USAN drug names under consideration

USAN Council’s statement on the use of USAN as domain names is that a name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names website shall be the effective equivalent of an intellectual property right for the relevant entities.

Visit United States Adopted Names FAQ to learn more.

Comments or protests should be addressed to Stephanie Shubat, USAN program director, American Medical Association, 330 North Wabash Ave., Suite 39300, Chicago, Illinois 60611, or via email: USAN@ama-assn.org.

In order to ensure your "under consideration" USAN domain name is available, you should consider purchasing the .com, .net and .org domain names of the USAN under consideration. The optimal time to do this is when you receive the letter from the USAN Program informing you of the USAN Council's naming decision.

The following names for the drugs described are "under consideration" by the USAN Council:

**August 2022**

*lefelsiran*: Treatment of alcohol use disorder (AUD)

**July 2022**

None

**June 2022**

*evacastinel*: Treatment of cognitive impairments in Parkinson’s Disease and dementia
evecostine: Treatment of cognitive impairments in Parkinson’s Disease and dementia

izadirib: Antineoplastic

nevadistine: Treatment of chronic pain conditions such as neuropathic pain and fibromyalgia

quoltistine: Treatment of chronic pain conditions such as neuropathic pain and fibromyalgia

rizevistine: Treatment of post-traumatic stress disorder (PTSD)

segnirotide: Treatment of diabetes and obesity

May 2022

enrustomig: Antineoplastic, treatment of cancer

vipalanebart: Treatment of migraine